Humana Inc. (HUM) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Humana Inc.'s unaudited financial results for the quarterly period ended September 30, 2024. Humana operates two primary reportable segments: Insurance (Medicare Advantage, Medicaid, Commercial, and Military services) and CenterWell (pharmacy, primary care, and home solutions). The company is currently executing a strategic exit from its Employer Group Commercial Medical Products business, expected to finalize in the first half of 2025.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $29.40 billion | $26.42 billion | $88.55 billion | $79.91 billion |
| Net Income (Attributable to Humana) | $480 million | $832 million | $1.90 billion | $3.03 billion |
| Diluted EPS | $3.98 | $6.71 | $15.72 | $24.26 |
| Operating Income | $728 million | $1.21 billion | $3.11 billion | $4.36 billion |
| Benefit Ratio | 89.9% | 86.6% | 89.2% | 86.2% |
| Operating Cost Ratio | 11.5% | 12.5% | 10.9% | 11.8% |
| Cash & Equivalents | $5.12 billion | $4.69 billion (Dec '23) | N/A | |
| Total Debt (Short + Long Term) | $13.02 billion | $11.66 billion (Dec '23) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.3% year-over-year (Q3) and 10.8% (YTD), driven by higher per-member Medicare premiums and growth in Medicare Advantage and state-based contract membership. This was partially offset by declines in stand-alone PDP and commercial fully-insured membership.
- Profitability Decline: Net income dropped 42.2% in Q3 and 37.3% YTD. This decline was significantly impacted by:
- Put/Call Valuation Adjustments: A $59 million charge in Q3 2024 related to non-consolidating minority interest investments (compared to a $35 million gain in Q3 2023).
- Value Creation Initiatives: Charges of $55 million in Q3 and $151 million YTD 2024, primarily asset impairments.
- Medical Cost Trends: Elevated medical cost trends in Medicare Advantage and state-based contracts increased the benefit ratio by 330 basis points in Q3.
- Segment Performance:
- Insurance Segment: Operating income fell 62.0% in Q3 due to higher benefit ratios, despite a 120 basis point improvement in the operating cost ratio.
- CenterWell Segment: Operating income decreased 4.5% in Q3, with the operating cost ratio increasing 100 basis points due to the v28 risk model revision impact on primary care.
- Debt & Liquidity: Total debt increased to $13.02 billion as the company issued $2.25 billion in new senior notes in March 2024 to refinance existing indebtedness and fund general corporate purposes. Cash flow from operations decreased significantly YTD ($3.5B vs $11.1B in 2023), largely due to the timing of a $7.1 billion Medicare premium remittance received early in September 2023.
Guidance, Outlook, Risks, and Contingencies
- Regulatory Litigation (RADV): Humana is actively litigating against the CMS "Final RADV Rule" which eliminates the "Fee-for-Service Adjuster" in risk adjustment audits. The company argues this violates the Administrative Procedure Act. A loss could materially adversely affect results of operations.
- Star Ratings Risk: CMS released 2025 Star Ratings showing a significant decline in plans rated 4-star or higher (from 94% in 2024 to ~25% in 2025). Humana has filed suit to vacate these ratings. If unsuccessful, this could negatively impact 2026 quality bonus payments and future revenues.
- Legal Settlements: In August 2024, Humana settled a qui tam suit regarding Medicare Part D actuarial equivalence for $90 million. The company is also defending against a putative stockholder class action filed in June 2024 alleging false statements regarding financial performance and medical costs.
- Business Exit: The company continues its planned exit from the Employer Group Commercial Medical Products business, with finalization expected in H1 2025. This has led to a 93.7% drop in commercial fully-insured membership.
- Value Creation: Management expects to incur additional charges related to value creation initiatives through the end of 2024.
Investor Verification Checklist
- Star Ratings Impact: Verify the status of the lawsuit challenging the 2025 Star Ratings and the potential financial impact on 2026 quality bonuses if the lawsuit is unsuccessful.
- Medical Cost Trends: Assess the sustainability of the elevated medical cost trends driving the increased benefit ratio (89.9% in Q3) and whether pricing adjustments for 2025 will be sufficient to offset them.
- Regulatory Exposure: Monitor the outcome of the RADV litigation and any potential retroactive recoveries or fines related to risk adjustment coding practices.
- Commercial Exit Progress: Track the timeline and costs associated with the final exit of the Employer Group Commercial Medical Products business.
- Investment Portfolio: Review the $998 million in gross unrealized losses on debt securities and the company's intent to hold these to maturity versus potential forced sales.